Suppr超能文献

他莫昔芬和来曲唑对早期和晚期乳腺癌女性甲状腺功能的影响:系统评价。

Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.

机构信息

Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.

Department of Biomedical Sciences, Center for Healthy Aging Copenhagen, University of Copenhagen, Copenhagen, Denmark.

出版信息

Cancer Med. 2023 Jan;12(2):967-982. doi: 10.1002/cam4.4949. Epub 2022 Jun 24.

Abstract

INTRODUCTION

Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti-oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. While the most common side-effects of this therapy are well-defined, less is known about its effects on thyroid function. In women treated for early BC, an average of 1-5 kg weight gain has been observed after treatment with chemotherapy/anti-oestrogens. We aim to evaluate the current knowledge on the side effects of tamoxifen and letrozole treatments on thyroid function, followed by its potential influence on the observed weight gain.

METHODS

We searched PubMed and found 16 publications on thyroid function and tamoxifen treatment in pre- and post-menopausal women with early- and advanced BC, whereas five publications on letrozole treatment in post-menopausal women with advanced BC.

RESULTS

According to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen-treated patients. Only one publication reported further significant changes in thyroid hormones beyond one year of tamoxifen treatment. No significant changes in thyroid function have been observed among letrozole-treated patients.

CONCLUSION

Tamoxifen-treated patients can develop mild and transient thyroid dysfunction within the first 12 months, yet further significant changes in thyroid function beyond one year of tamoxifen treatment have been reported in a single study. There is no evidence of thyroid dysfunction in letrozole-treated patients. Current literature does not focus on subclinical hypothyroidism as a possible cause of weight gain in patients with BC. Subgrouping of BC patients and studies with a longer observation of thyroid hormones and weight changes during and after anti-oestrogen treatment are needed to further elucidate how anti-oestrogens affect thyroid function.

摘要

简介

乳腺癌(BC)是女性中常见的癌症类型。治疗选择的进步导致了总体生存率的提高,但癌症治疗的副作用越来越受到关注。他莫昔芬和来曲唑等抗雌激素治疗在预防 BC 复发方面的有益效果已有充分记录。虽然这种治疗最常见的副作用已经得到很好的定义,但对其对甲状腺功能的影响知之甚少。在接受早期 BC 治疗的女性中,在接受化疗/抗雌激素治疗后,平均观察到体重增加 1-5 公斤。我们旨在评估他莫昔芬和来曲唑治疗对甲状腺功能的副作用的现有知识,然后评估其对观察到的体重增加的潜在影响。

方法

我们在 PubMed 上进行了搜索,找到了 16 篇关于早期和晚期 BC 绝经前和绝经后妇女接受他莫昔芬治疗以及 5 篇关于晚期 BC 绝经后妇女接受来曲唑治疗的甲状腺功能的出版物。

结果

根据目前的文献,他莫昔芬治疗的患者总体上存在轻度和短暂的甲状腺功能障碍,即亚临床甲状腺功能减退症。只有一项出版物报告了在他莫昔芬治疗超过一年后甲状腺激素进一步显著变化。来曲唑治疗的患者甲状腺功能无明显变化。

结论

在最初的 12 个月内,他莫昔芬治疗的患者可能会出现轻度和短暂的甲状腺功能障碍,但在一项研究中报告了在他莫昔芬治疗超过一年后甲状腺功能的进一步显著变化。来曲唑治疗的患者没有甲状腺功能障碍的证据。目前的文献并未将亚临床甲状腺功能减退症作为 BC 患者体重增加的可能原因。需要对 BC 患者进行亚组分析,并进行更长时间的观察,以阐明抗雌激素如何影响甲状腺功能,以及在抗雌激素治疗期间和之后甲状腺激素和体重变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e10/9883413/f188fbac3a51/CAM4-12-967-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验